ASCO 2022

ASCO 2022
June 03-07, 2022
Chicago, IL

American Society of Clinical Oncology 2022.

Explore more information for Gilead Oncology therapies
Results (8)

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results

Impact of magrolimab treatment in combination with azacitidine on red blood cells in higher-risk myelodysplastic syndrome (HR-MDS) patients

Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study

Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 Phase 1b study results

Primary Results From TROPiCS-02: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients With Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Advanced Breast Cancer

Trial in Progress: EVOKE-02: A phase 2 study of sacituzumab govitecan plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non−small-cell lung cancer (NSCLC)

Trial in Progress: EVOKE-01: A phase 3 study of sacituzumab govitecan (SG) vs docetaxel in patients with non-small cell lung cancer (NSCLC) progressing on or after platinum-based chemotherapy and checkpoint inhibitors

Exposure-Response Analyses of Sacituzumab Govitecan (SG) Efficacy and Safety in Patients (Pts) With Metastatic Triple-Negative Breast Cancer (mTNBC)